Eloxatin
Ampulla of Vater Carcinoma
Alliance for Clinical Trials in OncologyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Ampulla of Vater Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Docetaxel Minia University | Phase 3 | BB |
PANTOPRAZOLE Washington University School of Medicine | Phase 2 | CCC |
Dostarlimab UNICANCER | Phase 2 | CCC |
CIS-DIAMMINEDICHLOROPLATINUM II University of Nebraska | Phase 1 | CC |
Irinotecan University of Chicago | Phase 1 | CC |
ADH-1 TRIFLUROACETATE University of Nebraska | Phase 1 | CC |
FLUOROURACILUM Alliance for Clinical Trials in Oncology | Phase 1 | CC |
Same molecule, other indications
Eloxatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →